About Tune Therapeutics
Tune Therapeutics is a biotechnology company pioneering a new class of genetic medicine through epigenetic editing. Founded on cutting-edge advances in gene regulation mechanics, Tune has developed TEMPO, a proprietary platform that enables precise control over gene activity without cutting or permanently altering DNA sequences. Unlike traditional gene editing approaches that create irreversible deletions or knockouts, TEMPO can dial gene expression up or down in a graded, tunable, and reversible manner—from zero to up to 10,000x normal expression levels. The company's technology addresses a fundamental limitation in genetic medicine: the ability to treat not just rare single-gene disorders, but common, chronic, and age-related diseases that affect millions globally. TEMPO's modular design combines customizable DNA-binding domains (using modified Cas, ZFP, or TALE systems that cannot cut DNA) with effector proteins that alter epigenetic marks and chromatin accessibility. This approach allows Tune to target master controllers of cellular identity, steer stem cells toward specific pathways, replace cells lost to aging, repair age-damaged tissues, reduce chronic inflammation, and reverse gene dysregulation patterns underlying chronic diseases. Based in Durham, North Carolina and Seattle, Washington, Tune Therapeutics was founded by a veteran leadership team with deep expertise in gene and cell therapy, genome editing, and epigenetics. The company's lead program, Tune-401, is a first-in-class epigenetic silencer for Hepatitis B currently in Phase 1b/2a clinical trials. With its powerful multiplex capacity and integrated discovery-to-development process, Tune aims to bring gene, cell, and regenerative therapies into a new era—addressing the common and chronic diseases straining healthcare systems and limiting human healthspan on a global scale.
Mission & Story
Mission
We aim to bring gene, cell, and regenerative therapies into a new era of human medicine – to address the common and chronic diseases that are straining healthcare systems and limiting human healthspan on a global scale.
Founding Story
Tune Therapeutics was founded upon cutting-edge advances in the mechanics of gene regulation, built around a veteran leadership team with deep expertise in gene and cell therapy, genome editing, and epigenetics. Co-founders include Charles Gersbach, Fyodor Urnov, and Dan McHugh.
Clinical Focus
Medical conditions and clinical areas addressed by Tune Therapeutics.
Who It Serves
Milestones & Awards
Recent Milestones
Raised $175M in funding; Tune-401 entered clinical trials as first-in-class epigenetic silencer for Hepatitis B; Presented positive Phase 1b/2a data at EASL 2026; John McHutchison named CEO and Chairman of the Board; Featured in TIME Magazine on gene tuning technology
Awards & Recognition
Featured in TIME Magazine article 'The Power and Potential of Gene Tuning'
Social & Media
Latest Updates
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Repression With Tune-401 Epigenetic Silencer
Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics Unveils Breakthrough Data ShowingStable and Durable Epigenetic Regulation in Non-Human Primates
Company Details
- Headquarters
- Durham, NC, USA
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.